Status:
ACTIVE_NOT_RECRUITING
A Study of LY3532226 in Participants With Obesity
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 g...
Eligibility Criteria
Inclusion
- Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body mass index (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²)
- Have had a stable body weight that is less than or equal to 5% change in body weight for 3 months prior to screening and enrollment
Exclusion
- Have a lifetime history of a suicide attempt
- Have a history or presence of psychiatric disorders, including a history of major depressive disorder within the last 2 years
- Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire
- Have a known clinically significant gastric emptying abnormality, have undergone gastric bypass surgery or restrictive bariatric surgery
- Have taken approved or investigational medication for weight loss, within the previous 3 months or 5 half-lives of study screening, whichever is earlier
- Intend to use any weight-loss medications during study participation
- Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity
Key Trial Info
Start Date :
August 16 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
129 Patients enrolled
Trial Details
Trial ID
NCT06557356
Start Date
August 16 2024
End Date
December 1 2025
Last Update
November 20 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States, 32117
2
Fortrea Clinical Research Unit
Dallas, Texas, United States, 75247
3
Fortrea Clinical Research Unit
Madison, Wisconsin, United States, 53704
4
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623